Obstacles to effective immunotherapeutic anti-cancer approaches include poor immunogenicity of the tumour cells and the presence of tolerogenic mechanisms in the tumour microenvironment. We report an effective immune-based treatment of weakly immunogenic, growing solid tumours using a locally delivered immunogene therapy to promote development of immune effector responses in the tumour microenvironment and a systemic based T regulatory cell (Treg) inactivation strategy to potentiate these responses by elimination of tolerogenic or immune suppressor influences. As the JBS fibrosarcoma is weakly immunogenic and accumulates Treg in its microenvironment with progressive growth, we used this tumour model to test our combined immunotherapies. Plasmids encoding GM-CSF and B7-1 were electrically delivered into 100 mm 3 tumours; Treg inactivation was accomplished by systemic administration of anti-CD25 antibody (Ab). Using this approach, we found that complete elimination of tumours was achieved at a level of 60% by immunogene therapy, 25% for Treg inactivation and 90% for combined therapies. Moreover, we found that these responses were immune transferable, systemic, tumour specific and durable. Combined gene-based immune effector therapy and Treg inactivation represents an effective treatment for weakly antigenic solid growing tumours and that could be considered for clinical development.
Introduction
There is continued optimism that effective immunotherapeutic strategies can be developed for control of solid malignant cancers including their metastases. 1 This has resulted from an improved understanding of the tumour immune interactions, and the availability of cell, gene and ligand-based technologies to promote effector antitumour immune responses and to inactivate tolerogenic influences. It has been well established that the presence of a pronounced immune cell infiltrate within the primary cancer is associated with an improved prognosis and the elimination of micrometastatic disease. 2 In many cancers, however, there is minimal immune infiltrate. This lack of immunogenicity has been attributed to immune editing during tumour development, which results in cancers with minimal expression of tumour antigens, a downregulated expression of MHC class I molecules and antigen presentation capability, and T cell anergy due to the lack of costimulatory signalling. 3 A primary challenge with developing effective immunotherapy has been to upregulate the immune systems capability to target weakly immunogenic cells within growing tumours. A number of therapeutic approaches in patients with advanced disease, including enhancement of antigen presentation by ex vivo priming of antigen-presenting cells, vaccination strategies or the administration of tumour-specific T cell and cytokine therapies have resulted in transient anti-tumour responses, suggesting that weakly antigenic cancers are immune targetable. 4, 5 We have previously reported that a non-viral gene therapy, using a plasmid encoding the cytokine GM-CSF and the costimulatory molecule B7-1 delivered into a weakly immunogenic growing tumour in a mouse model resulted in the recruitment of effective cytotoxic anti-tumour responses and in the permanent elimination of 60% of established tumour masses. 6 These responses were tumour specific, durable and effective against a cancer, which was shown to be resistant to a diversity of preventive vaccination strategies.
Several studies suggest a preferential accumulation of T regulatory (Treg) cells within the mass of growing cancers relative to the systemic circulation, lymph nodes or spleen. [7] [8] [9] [10] These Treg (CD4 þ CD25 þ foxp3 þ ) cells may inhibit immune effector cells by direct intercellular influences or by secretion of inhibitory cytokines such as interleukin (IL)-10 and tumour growth factor-b. [11] [12] [13] The acquisition of this inhibitory capability in the tumour microenvironment is thought to explain the phenomenon of concomitant tumour immunity whereby the primary tumour mass can progress in the presence of an antitumour immune response, but there is an immune-based induction of dormancy or elimination of circulating tumour cells, which prevents emergence of metastatic disease in some.
14 In experimental cancers and in patients with advanced ovarian cancers, depletion of Treg inhibits the growth of tumour masses, suggesting a potential for this form of therapy in immunotherapeutic protocols. 8, 15 In this study, we investigated the potential for a combined immunotherapeutic approach to the curative treatment of established murine fibrosarcomas-immunogene therapy of the tumour mass to promote intratumoural antigen presentation and effector recruitment and Treg inactivation to reduce inhibitory or tolerogenic immune cell influences in the tumour environment.
Materials and methods

Mice and tumour cell lines
Balb/C or MF1-nu/nu mice (6-8 weeks of age) were purchased from Harlan Laboratories (Oxfordshire, UK) and used in accordance with the institutional guidelines for animal care. All experiments were approved by the animal ethics committee of University College Cork. The JBS (murine fibrosarcoma) cell line was established and maintained as described earlier. 6 Induction of this tumour is not preventable by prior vaccination with cells in a diversity of protocols. 6 The C26 cell line was obtained from the ATCC and cultured in Dulbecco's Modified Eagle Medium (Sigma-Aldrich, Dublin, Ireland). Tumour induction in all experiments was by subcutaneous (s.c.) injection of 2 Â 10 6 JBS cells or 5 Â 10 4 C26 cells in 200 ml of serum-free Dulbecco's Modified Eagle Medium. Tumour volume was calculated according to the formula V ¼ ab 2 P/6, where a is the longest diameter of the tumour and b is the longest diameter perpendicular to diameter a. From these volumes, tumour growth curves were constructed. In cases of successful treatment, 100 days with no recurrence was considered as cure.
Plasmid construction
The mammalian expression vector pMG was purchased from Invivogen (Cayla SAS, Toulouse, France). A version of this plasmid, designated pGT141, containing the murine GM-CSF and human B7-1 genes transcriptionally controlled from the hEF1 HTLV and CMV promoters, respectively, was designed and cloning was performed on contract by Invivogen. Human B7-1 cDNA has been shown previously to function in a murine setting. 16 The inserts were confirmed by sequencing. Plasmids were then prepared using an endotoxin-free method (Qiagen, West Sussex, UK).
Flow cytometry analysis FACS analysis was performed using anti-mouse CD3e-PE-Cy5 (145-2C11), anti-mouse CD4-FITC (GK1.5), anti-mouse CD25-APC (PC61.5) or (7D4), anti-mouse CD8-FITC (53-6.7), anti-mouse foxp3-PE (FJK-16s), anti-mouse Fc block (CD16/32) and relevant isotype controls as per the manufacturer (eBiosciences, Insight Biotechnology, UK). Flow cytometry staining was performed using a standard protocol. Briefly, spleen, tumour draining lymph node and tumour tissue were excised, finely minced using a scalpel and then mechanically disassociated by pushing through a 20 mm pore nylon filter (Falcon, Becton Dickinson (BD), Oxford, UK) suspended in RPMI (Sigma-Aldrich). Splenic cell pellets were treated with lysis buffer to eliminate erythrocytes and washed twice in staining buffer (1% FCS, 5% BSA, PBS). Lymph node and tumour tissue were washed and resuspended in FACS staining buffer. Cell counts were determined using a haemocytometer and resuspended at a concentration of 1 Â 10 6 cells per 100 ml. Staining was performed following optimization in the laboratory (data not shown). Analysis was preformed on a FACSCalibur (BD) and analysed using Cell Quest Pro Software (BD).
In vivo Treg cell inactivation
Anti-CD25 antibody (Ab) (PC61) and Rat IgG1 (HRPN, anti-peroxidase horseradish) as a control were purchased from Bio-Express, NH. Systemic Treg inactivation was validated using FACS analysis of alterations in Treg cell numbers in response to varying doses of Ab. The minimum dose required of Ab was 1 mg kg À1 delivered intraperitonealy to achieve 495% reduction in systemic Treg cell numbers without non-specific T-cell activation (J Lederer, personal communication). Validation that the control Ab had no effect on Treg numbers was achieved using FACS.
In vivo gene therapy
When tumors reached B100 mm 3 in volume (5-7 mm major diameter), mice were randomly divided into experimental groups and subjected to specific experimental protocols. Mice were anaesthetized during all electroporation treatments by intraperitoneal administration of 200 mg xylazine and 2 mg ketamine. For DNA delivery, a custom-designed applicator with two needles 4 mm apart was used, with both needles placed through the skin central to the tumour. Tumours were injected between electrode needles with 1 mg plasmid DNA in sterile injectable saline per mm 3 tumour in an injection volume equal to that of the tumour unless otherwise noted. After 80 s, square-wave pulses (1200 V cm À1 100 ms Â 1 and 120 V cm À1 20 ms, eight pulses) were administered in sequence using a custom-designed pulse generator (CythorLab, Aditus, Lund, Sweden). In all cases, a drop in impedance measurement was taken as evidence for successful tissue cell poration. Validation of gene expression after electroporation gene delivery was performed as previously published 17 using the reporter gene for luciferase and in vivo imaging. Plasmids coding for GM-CSF and B7-1, designated pGT141, or the corresponding gene-free version (designated pMG) were used accordingly.
In vitro cytotoxicity assay To assay for cytotoxic T lymphocyte (CTL) activity against JBS cells, splenocytes were harvested from mice responding to treatment and resistant to tumour growth on rechallenge with JBS and control animals. The protocol was as follows, the spleen was harvested and to induce tumour-specific lymphocytes, 2 Â 10 6 splenocytes were incubated with 2 Â 10 5 mitomycin C-treated JBS cells in the presence of 25 IU ml 
Statistical analysis
At each time point, a two-sampled t-test was used to compare mean tumour volume within each treatment group. Microsoft Excel 11.0 (Microsoft) was used to manage and analyse data. Statistical significance was defined at the standard 5% level.
Results
CD4
þ CD25 þ foxp3 þ T cells increase in the tumour environment FACS analysis demonstrated a marked increase in the total number of CD4 þ CD25 þ T cells in response to tumour growth, with the percentage of these cells being 470% of total lymphocytes, at large tumour volumes (data not shown). Moreover, when CD4 þ T cells were stained for intracellular foxp3, a transcription factor critical for mouse Treg cell differentiation and function, there was a significant increase in the total number of intratumoural Tregs, (
, in large volume compared with small volume tumours ( Figure 1a ). To address whether tumour load may also cause a systemic increase in Tregs, we assessed Treg levels in spleen and tumour draining lymph nodes in animals bearing large or small tumours. The numbers of CD3 þ CD4 þ T cells were consistent between small and large tumour groups and similar percentages of Tregs were observed in the spleens regardless of tumour size (Figure 1b) . These data suggest that Tregs accumulate at the tumour site in response to tumour growth with no corresponding increase in the percentage of systemic Tregs. 
Treg cell inactivation at tumour induction causes tumour regression
To optimize the timing for anti-CD25 Ab administration in our mouse tumour model, single administrations of Ab at various time points were tested for their efficacy at inhibiting tumour growth. As shown in Figure 3a , the combination of a treatment at 1 day before and 4 days after tumour induction resulted in 100% of animals clearing their s.c. tumour with no evidence of recurrence up to 100 days after inoculation. Irrelevant Rat IgG Ab when administered at an equivalent dose and time had no significant effect on tumour growth or survival when compared with untreated tumours.
Treg inactivation at the time of tumour induction results in a systemic, durable and antigen-specific T lymphocyte-mediated anti-tumour immune responses All 'cured' animals were resistant to re-challenge with tumourigenic doses of the same tumour, which they had cleared at 4100 days and 4300 days post-initial tumour inoculation (Figure 3b ). However, when such animals were challenged with a tumourigenic dose of a different antigenic tumour, C26, all, 24 'cured' mice in repeated experiments succumbed to tumour challenge, (Figure 3c ). To show that the response was T-cell mediated, athymic MF1 nu/nu mice were inoculated with tumourigenic doses of JBS in the right flank and treated with anti-CD25 mAb, Rat IgG or untreated, as per previous protocol 1 day before and 4 days after tumour inoculation and resultant data showed no significant difference in tumour growth rate or survival between any groups (Figure 3d ).
Treg cell inactivation in mice with established tumours Mice bearing established tumours of 100 mm 3 were randomized into groups to receive anti-CD25 Ab, Rat IgG as described earlier with two doses of Ab 5 days apart or no therapy. This resulted in a reduced growth rate of JBS tumours in mice receiving anti-CD25 mAb versus no therapy or irrelevant Ab (Figure 4a ). There was a 20% 'cure' rate in those mice with established JBS tumours (Figure 4b) , and rechallenge studies with a different antigenic tumour as discussed and shown in Figure 3 demonstrated that this response is likely to be tumour specific.
Immune gene therapy increases intratumoural T-effector cell numbers Similar to previously published data, the immunogene therapy delivered via electroporation gave a 60% cure rate in s.c. JBS tumours. 6 We investigated what effect the delivery of GM-CSF/B7-1 via electroporation had on immune subpopulations in the tumour. Confirmation of expression of GM-CSF and B7-1 was performed as published previously by our group. 6, 17 On attaining a treatment size of 100 mm 3 , tumours were electroporated alone or with GM-CSF/B7-1 or were left untreated. After 72 h, tumours were excised and stained for T-effector cells (CD8 þ ) and Treg (CD4 þ CD25 þ ) cells. A significant increase was seen in the total number of T-effector cells in those tumours treated with GM-CSF/B7-1 versus electroporation alone (Po0.02) versus no treatment (Po0.05) (Figure 5a ). There was a significant reduction of the CD4 þ CD25 þ cell population (Po0.02) within those tumours treated by immunogene therapy in comparison with the untreated tumours but not with the null plasmidtreated group (Figure 5b ).
Immune gene therapy effects are augmented by Treg cell depletion
We examined the effect on tumour growth in mice treated with a combination of immunogene therapy and anti-CD25 Ab. For these studies, mice were treated with two doses of anti-CD25 Ab 5 days apart and 100 mm 3 tumours (c. day 11) were electroporated with plasmid encoding GM-CSF/B7-1. The combination in JBS led to a significant reduction (Po0.001) in the tumour growth rate and an improvement in survival (Po0.05) with the addition of anti-Treg Ab to immune gene therapy versus alone or with control Ab. There was complete rejection of tumours in 490% of the animals (Figures 6a and b) . Electroporation controls have previously been published and are not shown here. 6 In vitro and in vivo cytoxicity assays In vitro and in vivo CTL assays were performed to determine the influence of these therapies on anti-tumour immunity. On combination therapy, there was a significantly increased cytotoxic response in vitro compared with control-treated mice (Figure 6c ). To test whether the JBS immunity was transferable, we performed adoptive transfer experiments using a modified Winn assay, 6, 18 where groups of mice received injections of a mixture of JBS cells and splenocytes from either combination-treated mice or naive mice. All mice receiving splenocytes from 'cured' mice failed to grow tumours, whereas JBS tumours developed in all the control animals receiving splenocytes from naive mice (Figure 6d) . Furthermore, this effect was sustained with all surviving mice being resistant to a further JBS tumour challenge. Collectively, these findings suggest that the anti-tumour immunity observed in mice treated with Treg inactivation therapy and intratumour immunogene therapy was tumour specific and provides long-term resistance to tumour challenge.
Discussion
We have shown that a combination of immunotherapeutic strategies aimed at simultaneously stimulating the immune effector system and attenuating the T regulatory system within the tumour environment is an effective treatment for a weakly immunogenic tumour, with complete eradication of growing tumour masses from most animals. The combined therapies were more effective than either treatment alone, appeared safe and without apparent side effects, suggesting that this strategy may have potential for clinical development. The improved efficacy of treatment and vaccination protocols following combination with Treg inactivation has been suggested in earlier studies [20] [21] [22] Indeed, Treg inactivation has been reported, in humans, to result in significant therapeutic responses in advanced ovarian and renal malignancies without apparent side effects. 15, 23 It is possible that this inhibition of the Treg system is mainly where there are high concentrations of activated Tregs and, when combined with immune effector EP GMCSF/B7-1 Tumour Figure 5 Immunogene therapy increases intratumoural T-effector cell numbers. Subcutaneous JBS tumours were electroporated with plasmid encoding GM-CSF/B7-1 or no plasmid. At 72 h after electroporation, the tumours were excised and stained for CD3 þ , CD8 þ , CD25 þ and CD4 þ . (a) It was noted that there was an increase in the total number of activated T-effector cells in those tumours that received immune gene therapy. (b) Moreover, there was a decrease in the total number of activated CD4 cells at this time point. These plots are representative of groups with three mice per group, the experiment was repeated twice. preferentially targeted the higher CD25 receptor expressing cells. Ideally, we would have shown the inactivation of the immune regulatory cells in the local tumour environment but with rapid tumour regression we were unable to achieve this. It is also possible that there was additional local Treg inactivation by the combined therapy as there were fewer Treg cells in tumours treated by the immune gene therapy. Treg competence in the systemic compartments was fully recovered after 3 weeks, suggesting that in this treatment protocol, a short period of inactivation therapy would suffice. It is also encouraging that on long-term follow-up for 1 year, the cured mice did not outwardly manifest autoimmune disease, indicating that the immunogene therapy and short-term inactivation of Tregs did not induce autoimmune responses to normal tissues and that the anti-tumour responses were non-cross reactive with normal tissues.
In this model, the responses were tumour specific, indicating an upregulation of the immune system to antigens in an otherwise unresponsive or weakly immunogenic tumour. This is important, as it indicates that effective anti-tumour responses may be achievable without antigen isolation or ex vivo manipulations and to poorly immunogenic tumours. Thus, repeat treatment and induction of new immunological responses to less immunogenic tumour cells could also be feasible with this protocol. In this model, Treg inactivation alone was not as effective as reported by others in different tumours 8 but had a markedly additional curative effect when combined with the immunogene therapy. This suggests that weakly antigenic tumours may not evoke significant unassisted immune reactivity and that Treg depletion alone would be less effective than when used in treatment of tumours where there are concomitant immune responses. We have previously found that the growing JBS tumour does not evoke significant concomitant anti-tumour immune responses, but effective control of metastatic growth was achievable by the immunogene therapy as an adjuvant to surgery. 17 It is, therefore, likely that the immunogene therapy sensitized the immune system to the weak antigens by facilitating recruitment, viability and maturation of antigen-presenting cells in the tumour environment.
In keeping with tumour clearance in 60% of animals treated by immunogene therapy, there were augmented effector responses. In an earlier study, we found that both expression of the B7-1 molecule and GM-CSF production by the tumour cells contributed to the responsiveness. 6 We also found that tumour rejection was due to a generalized apoptotic tumour cell death but that transgene expression occurred in o10% of the tumour cells. This suggests that the induced immunological responses were effective against non-transfected tumour cells and gene transfection of all tumour cells is not necessary for tumour eradication. Similarly, the emergence of distal metastases can be forestalled by immunogene therapy of the primary tumour making it also an attractive proposition for development as a neoadjuvant therapy, as it is likely that minimal residual cancerous disease shares the same antigen spectrum as the primary tumour. 17 In this study, we also confirm other reports of local accumulation of Treg cells in response to tumour growth. 24, 25 A number of studies have shown both direct intercellular and cytokine-induced inhibition of effector cells by Tregs. 26, 27 It is likely that inhibition of Tregs augmented the anti-tumour efficacy without numerical increases of the effector cells. It is not known whether neutralization of Treg cytokines such as IL-10 would have the same efficacy as Treg inhibition, although encouraging results have been found by others in different models. 28 This study suggests that reduction of Treg influences may have occurred both from the immunogene therapy and the Ab treatment and that augmentation of the intratumoural CD8 cell numbers was seen after the immunogene therapy. As has been well documented, the T-cell receptor is not uniquely expressed on Tregs. 29 We used a low dose of Ab that targeted the CD25 þ high-expressing cells, the majority of which have a regulatory phenotype and which possibly also did not give rise to a non-specific immune response or a detrimental effect on the T effector population. CD25 expression on Treg cells has a functional role such that interruption of the IL-2R/IL-2 signalling pathway blocks Teffector function via changes in the glucocorticoid-induced TNFR family gene. Many studies have been published that deal with the functional and cellular effects observed following anti-CD25 Ab administration in both tumour and autoimmune murine models. 19, 22, 30 In humans, denileukin difitox (Ontak) treatment, which also targets the CD25 receptor, resulted in dramatic responses of advanced renal cancers, which coincided with Treg depletion in the tumour environment. 23 The challenge to date has been to find an alternative target to provide a short-term specific elimination of the Tregs that may be clinically useful and would not eliminate CD4 helper or CD8 effector cells. It is interesting that vaccination of mice with foxp3 mRNAtransfected dendritic cells has been shown to elicit a foxp3-specific cytotoxic T-lymphocyte response, which led to preferential depletion of Tregs in the tumour and not systemically. 31 It is not known whether such an approach might increase the long-term risks of autoimmune-based diseases.
We conclude that a combination of immunogene therapy and Treg cell depletion resulted in the complete eradication of weakly immunogenic growing solid tumours. The combination therapy was more effective than either modality alone. The anti-tumour responses were immune based, tumour specific and durable. There were no apparent side effects to the treatment. This treatment protocol has potential for the development for clinical application as either a primary or neoadjuvant therapy. This study also shows that an effective immunebased therapy could be achieved without prior characterization or manipulation of the tumour antigens. This suggests that individual patient-based immune therapies might be developed, which is important as the tumour antigen spectrum and immune responsiveness can vary at different phases of tumour growth or between patients for any particular cancer type.
